Trial Profile

Integrating Long-Acting Injectable Treatment to Improve Medication Adherence Among Persons Living With HIV and Opioid Use Disorder

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buprenorphine (Primary) ; Cabotegravir+rilpivirine (Primary)
Indications HIV-1 infections; Opioid-related disorders
Focus Adverse reactions
Acronyms CHOICE

Most Recent Events

20 Feb 2026 Status changed to withdrawn prior to enrolment.
26 Dec 2025 Actual primary completion date is 27 Aug 2025.
26 Dec 2025 Phase of the study changed from phase 0 to phase 2.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com